

Available online at www.sciencedirect.com

European Journal of Pharmaceutics and Biopharmaceutics 70 (2008) 215–225

**European
Journal of
Pharmaceutics and
Biopharmaceutics**
www.elsevier.com/locate/ejpb

Research paper

Comparative evaluation of interpolyelectrolyte complexes of chitosan with Eudragit[®] L100 and Eudragit[®] L100-55 as potential carriers for oral controlled drug delivery

Rouslan I. Moustafine^{a,*}, Evgeniya B. Margulis^a, Liliya F. Sibgatullina^a, Vera A. Kemenova^c, Guy Van den Mooter^b

^a Department of Pharmaceutical, Toxicological and Analytical Chemistry, State Medical University of Kazan, Tatarstan, Russian Federation

^b Laboratorium voor Farmacotechnologie en Biofarmacie, University of Leuven, Leuven, Belgium

^c Scientific Center for Biomedical Technologies, State Research Institute of Medicinal and Aromatic Plants (VILAR), Moscow, Russian Federation

Received 4 September 2007; accepted in revised form 7 April 2008

Available online 22 April 2008

Abstract

With a view to the application in oral controlled drug delivery systems, the formation of interpolyelectrolyte complexes (IPEC) between chitosan (CS) and Eudragit[®] L100 (L100) or Eudragit[®] L100-55 (L100-55) was investigated at pH 6.0, using elementary analysis. The interaction or binding ratio of a unit molecule of CS with Eudragit[®] L copolymers depends on the molecular weight of CS, and changes from 1:0.85 to 1:1.22 ($1.17 < \varphi < 0.82$) for L100 and from 1:1.69 to 1:1.26 ($0.60 < \varphi < 0.79$) for L100-55, respectively. Based on the results of FT-IR, the structure of the IPECs can change substantially as a function of pH (from 5.8 till 7.4). Swelling behavior of physical mixtures (PM) is definitely different, and potential interactions between the two polyelectrolytes were not observed. The release of the model drug diclofenac sodium (DS) was significantly delayed from tablets made up of the IPEC and can be modified by two ways: choosing Eudragit[®] L copolymer types and/or changing the molecular weight of CS in the IPECs composition.

© 2008 Elsevier B.V. All rights reserved.

Keywords: Interpolyelectrolyte complex; Eudragit[®] L100; Eudragit[®] L100-55; Chitosan; Infrared spectroscopy; Elementary analysis; Diclofenac sodium; Oral controlled drug delivery

1. Introduction

Modification of the properties of a polymer can be obtained by copolymerisation or derivatisation, a strategy

Abbreviations: IPEC, interpolyelectrolyte complex; CS, chitosan; CS_{LW}, low molecular weight chitosan; CS_{MW}, medium molecular weight chitosan; CS_{HW}, high molecular weight chitosan; MW, molecular weight; L100, Eudragit[®] L100; L100-55, Eudragit[®] L100-55; PM, physical mixture of the polymers; DS, diclofenac sodium; SIT, simulated the intestinal tract; GIT, gastro-intestinal tract.

* Corresponding author. Department of Pharmaceutical, Toxicological and Analytical Chemistry, State Medical University of Kazan, Butlerov str., 49, 420012 Kazan, Tatarstan, Russian Federation. Tel.: +7 843 2360451, fax: +7 843 2360393.

E-mail address: mustaf@rambler.ru (R.I. Moustafine).

that was successfully applied in the past. However, the major drawback of this approach is that new chemical entities are introduced with an unknown toxicological profile. Before these products can be evaluated in animals and also in human clinical trials, a lot of time and resources must be spent to safety evaluation. A sound approach to overcome this problem is the physical modification of the polymer, rather than the chemical. In this respect interpolyelectrolyte complexes (IPEC) may provide a valuable tool to design drug delivery systems with specific physicochemical properties.

IPEC with polysaccharides, obtained as precipitates on mixing cationic with anionic polymers in aqueous solutions, have been reported previously, mostly with participation of chitosan (CS) as polycation. The advantages